APP and Alzheimer disease: Although activation of the complement system or a lipopolysaccharide (LPS) treatment in amyloid precursor protein (APP) transgenic mice increases phagocytosis of Aβ and might limit pathology by activating immune responses [8,9], the beneficial role of inflammation in AD does not seem to be sufficient to halt or reverse the disease.